Fauci Gets the Giggles When Asked Why White House is Spreading Disinformation About COVID Vaccine Availability


Posted originally on the conservative tree house on May 13, 2022 | Sundance 

Fake News CNN’s Jake Tapper asks White House Chief Medical Advisor Anthony Fauci why the White House is sending out false information, aka ‘disinformation’, about when the COVID vaccines were available. Fauci giggles, laughs and says “I have no idea.”  WATCH:

U.S. politics has devolved into a grand pretense of a theatrical performance keeping everyone distracted from the severe damage being inflicted by the political ideologues within the Biden administration.

I guarantee you if someone were just to ask Joe Biden at a presser who his Interior Secretary or EPA Administrator were, he’d have absolutely no idea.  Biden is purposefully and completely isolated from the policies being carried out by the people running the administration.  Biden has no idea what they are doing. None.

Clueless and disconnected Joe Biden is a shallow, empty and at times explosively angry vessel of nothingness.   The entire world can see it.

Australia Launches Booster Shot Marketing Campaign


Armstrong Economics Blog/Vaccine Re-Posted May 13, 2022 by Martin Armstrong

The Australian government is spending millions on an ad campaign to encourage citizens to take a third COVID vaccine. Their method of marketing is quite surprising and I question who would be enticed to take the vaccine upon watching this ad. The campaign features individuals who received the two jabs — and still fell deathly ill with COVID.

You risked your life to take an experimental vaccine, twice, and STILL contracted the virus. Your symptoms were allegedly life-threatening, so the theory that the vaccine will lessen symptoms is moot here. All of that and people are still willingly taking the third vaccine. Cognitive dissonance is strong here.

Nearly 72% of Southern Australians are triple jabbed, yet the government feels it is worth spending $2 million to target that remaining portion who likely do not want another useless vaccine with known side effects. Governments across the globe were hoping we would all be mindless sheep, politely queuing each season for another immunization. Enough is enough.

Major Medical Mystery: Why Some People Despite Exposure Don’t Get COVID


By joelshirschhorn medical researcher, analyst at Joel S. Hirschhorn | Telling the truth with good data Published originally on TrialSite News on May. 12, 2022, 9:00 a.m.

A global medical mystery is being aggressively pursued by medical researchers.  The core issue is that a relatively small fraction of people despite high exposure to COVID have not gotten ill with COVID infection.  Think of health workers in hospitals in contact with many seriously ill COVID patients.  Also, members of households that stood out because unlike others in the home who got ill with COVID they did not get infected.  The mystery is what explains how highly exposed individuals did not get ill with COVID infection.

There are two main ways of explaining resistance to COVID.  One is that some people have strengthened their immune systems by any of a number of actions taken before or during the pandemic.  For example, some may have elevated levels of vitamin D in their blood by taking high doses of supplements.  The other explanation that appeals to medical researchers is that some people have a genetic makeup that gives them total defense against COVID infection,

Market from Volume to Targeted Boosts


TrialSite Staff by Staff at TrialSite | Quality Journalism May. 10, 2022, 9:00 a.m.

After 16 months of major COVID-19 immunization initiatives worldwide, government appetite for COVID-19 vaccine products appears to morph into a more focused, market-based, targeted booster series, a change that vaccine producers are now adjusting to accommodate. With a confluence of forces, from COVID-19 vaccine gluts to increasing numbers of producers to leeriness of waning effectiveness due to highly transmissible variants, the market drivers, heavily driven by government, give way to an unfolding new reality.

In the United States, like in many other nations, including those aligned with the World Health Organization (WHO), centered responses to COVID-19 emphasized production and distribution of a maximum number of vaccines with targets of achieving at least 70% vaccination. That effort, again coordinated to some degree by groups such as WHO, led to the inoculation of about 4.68 billion people (according to Our World in Data) worldwide, or neatly 60% of humanity, representing an unprecedented pandemic response.

Vaccine producers such as Pfizer, Moderna, Johnson and Johnson (Janssen), AstraZeneca, and others understand that unless there are continued government mandates effectively priming the pump of demand, those individuals with a preference for COVID-19 immunization have already gone ahead with the procedure.

What’s left is a market for boosters and what could become some sort of annual shot available for targeted populations. Of course, in some markets, young children are still a target for COVID-19 vaccines.  Regardless, companies now operate in a quite different environment now, than they did in the period of late 2020 through 2021: a period driven by massive government spending, heavy industry influence on the regulatory process, risk-sharing, and the like to a more traditional competitive marketplace.

The Last Market: Young Children

While the children’s markets in places like America are still relevant, awaiting approval, what’s becoming apparent will be the emphasis on booster shots. In the world’s most lucrative drug market, America, Pfizer, and Moderna will more than likely persist as market leaders vying for the parental demands of children as public health agencies such as the CDC continue to emphasize that the risk-benefit analysis of the COVID-19 vaccine favor by a long-shot vaccination. The point of view is that there are no risk-free choices and that it’s better to be safe than sorry with the very youngest members of society. 

To date, the CDC recommends the Pfizer vaccine for both the 5-11 age and 12 to 17 cohort while not recommending Moderna. Under 4 is the last market segment the vaccine makers vie for, and if the FDA authorizes, then Pfizer would own that market. A potential battle emerges over this cohort (aged 4-11) as a growing movement concerned for the safety associated with the vaccines, especially the mRNA-based products, gains momentum to question the mass vaccination on this young population. Critics argue that the original premise for mandates and the like was to control community transmission.  Given substantial waning vaccine effectiveness combined with mutating variants, critics suggest the risks of serious infection and death are too low, and the safety issues are higher than the government is letting on. 

Demand for Vaccines Wane

But demand for vaccines is flat in much of the world. In America, there is little uptick in vaccination as the “fully vaccinated” defined as receiving the two jabs of either Pfizer-BioNTech, Moderna or one jab from Janssen equals 66.8% of the population while about 30.7% of the population opted for a booster dose.

Meanwhile, TrialSite, on several occasions, has chronicled a global glut of COVID-19 vaccines and therapeutics, especially in places like India, the world’s second-highest populated country. In places like Australia, where the death rate associated with COVID-19 has absolutely skyrocketed despite high immunization rates, the public health agencies and politicians continue to promote booster doses as the answer. TrialSite reported recently that Australian politicians in an election season essentially pretend that times are back to normal despite record numbers of cases, near-record hospitalizations, and double the deaths in the first months of 2022 than all of 2020 and 2021 combined.

Some Possible Explanations

Reuters’ Michael Erman and Manas Mishra write that vaccine producers such as Novavax and CureVac, the German mRNA-vaccine maker in partnership with GlaxoSmithKline, seek to target this booster market. Novavax still awaits FDA authorization despite the fact that much of the developed world, from Europe to Canada and Japan to the WHO, have authorized the use of the Novavax vaccine.

Meanwhile, the outlook for Janssen and AstraZeneca (Oxford) is that bright, report the Reuters journalists. According to Hartaj Singh, an analyst from Oppenheimer & Co., “It becomes a very competitive game with companies battling it out with pricing and for market share, even for vaccines that are considered to be the best, like Pfizer and Moderna.”

Interestingly, Pfizer’s CEO Albert Bourla went on the record in an interview recently that those adults that have opted to receive a COVID-19 vaccine are not likely to start accepting shots now in a recognition that the mega push for vaccine administration has come and gone.

Moderna has pegged the unfolding market as the annual shot market, targeting the following:

  • Adults 50 and above
  • People with comorbidities or other risks
  • High-risk occupations (e.g., healthcare, etc.)

According to the estimates of Stephane Bancel, Moderna’s CEO, this emerging annual shot market totals 1.7 billion, representing 21% of the global population. The mRNA-based vaccines are more expensive and cumbersome to distribute and store, hence a sizeable chunk of that estimated target may opt for other vaccines such as the two recently touted by vaccine insiders at WHO including a plant-based vaccine from Canada and one from China. 

More than likely Western Europe and America will represent central markets for sales for Pfizer and Moderna who will move toward more competitive, targeted responsive strategies as large government pre-purchases are probably going to be far less. Moreover, TrialSite suggests what were cozy relationships between industry and government agencies will become less so as the various governments’ responses to the pandemic will be a hot topic, especially in democracies in current election cycles.

Key Question: A flu shot model or something else?

The Reuters writers posed an important question in the recent piece: will the likes of Pfizer and Moderna starting this fall market a tailored, redesigned vaccine targeted relevant variants of concern (e.g., Omicron, BA.2, etc.)?

Both Moderna and Pfizer executives are on the record that they are developing Omicron-targeted vaccines.

This becomes an important topic as even the mainstream media starts to become slightly critical of the pandemic response, including mRNA-based vaccine makers that never modified the vaccine product once. The vaccine authorized and approved in the United States was developed based on the original Wuhan variant of SARS-CoV-2 which didn’t seem to make it in circulation to America nor most of the world.

Revenues Decline (but still unprecedented)

2023 sales numbers, while still staggering as compared to historical precedent in the pharmaceutical industry, are nonetheless, on the decline. Reuters reports $17 billion projected for Pfizer-BioNTech (down nearly half from $34 billion) and $10 billion for Moderna as compared to $23 billion in 2022. Sales will continue to drop because enormous fortunes were generated in the winner-take-all pandemic market.

TrialSite suggests the COVID-19 pandemic response must be seriously evaluated due to levels of bias, political interference, and potentially corruption at an unprecedented level. Should the political conditions change in the United States for example, leading to serious inquiries, the pandemic winners may incur unexpected costs.

After 16 months of major COVID-19 immunization initiatives worldwide, government appetite for COVID-19 vaccine products appears to morph into a more focused, market-based, targeted booster series, a change that vaccine producers are now adjusting to accommodate. With a confluence of forces, from COVID-19 vaccine gluts to increasing numbers of producers to leeriness of waning effectiveness due to highly transmissible variants, the market drivers, heavily driven by government, give way to an unfolding new reality.

In the United States, like in many other nations, including those aligned with the World Health Organization (WHO), centered responses to COVID-19 emphasized production and distribution of a maximum number of vaccines with targets of achieving at least 70% vaccination. That effort, again coordinated to some degree by groups such as WHO, led to the inoculation of about 4.68 billion people (according to Our World in Data) worldwide, or neatly 60% of humanity, representing an unprecedented pandemic response. TrialSite Staff by Staff at TrialSite | Quality Journalism

May. 10, 2022, 9:00 a.m.

After 16 months of major COVID-19 immunization initiatives worldwide, government appetite for COVID-19 vaccine products appears to morph into a more focused, market-based, targeted booster series, a change that vaccine producers are now adjusting to accommodate. With a confluence of forces, from COVID-19 vaccine gluts to increasing numbers of producers to leeriness of waning effectiveness due to highly transmissible variants, the market drivers, heavily driven by government, give way to an unfolding new reality.

In the United States, like in many other nations, including those aligned with the World Health Organization (WHO), centered responses to COVID-19 emphasized production and distribution of a maximum number of vaccines with targets of achieving at least 70% vaccination. That effort, again coordinated to some degree by groups such as WHO, led to the inoculation of about 4.68 billion people (according to Our World in Data) worldwide, or neatly 60% of humanity, representing an unprecedented pandemic response.

Vaccine producers such as Pfizer, Moderna, Johnson and Johnson (Janssen), AstraZeneca, and others understand that unless there are continued government mandates effectively priming the pump of demand, those individuals with a preference for COVID-19 immunization have already gone ahead with the procedure.

What’s left is a market for boosters and what could become some sort of annual shot available for targeted populations. Of course, in some markets, young children are still a target for COVID-19 vaccines.  Regardless, companies now operate in a quite different environment now, than they did in the period of late 2020 through 2021: a period driven by massive government spending, heavy industry influence on the regulatory process, risk-sharing, and the like to a more traditional competitive marketplace.

The Last Market: Young Children

While the children’s markets in places like America are still relevant, awaiting approval, what’s becoming apparent will be the emphasis on booster shots. In the world’s most lucrative drug market, America, Pfizer, and Moderna will more than likely persist as market leaders vying for the parental demands of children as public health agencies such as the CDC continue to emphasize that the risk-benefit analysis of the COVID-19 vaccine favor by a long-shot vaccination. The point of view is that there are no risk-free choices and that it’s better to be safe than sorry with the very youngest members of society. 

To date, the CDC recommends the Pfizer vaccine for both the 5-11 age and 12 to 17 cohort while not recommending Moderna. Under 4 is the last market segment the vaccine makers vie for, and if the FDA authorizes, then Pfizer would own that market. A potential battle emerges over this cohort (aged 4-11) as a growing movement concerned for the safety associated with the vaccines, especially the mRNA-based products, gains momentum to question the mass vaccination on this young population. Critics argue that the original premise for mandates and the like was to control community transmission.  Given substantial waning vaccine effectiveness combined with mutating variants, critics suggest the risks of serious infection and death are too low, and the safety issues are higher than the government is letting on. 

Demand for Vaccines Wane

But demand for vaccines is flat in much of the world. In America, there is little uptick in vaccination as the “fully vaccinated” defined as receiving the two jabs of either Pfizer-BioNTech, Moderna or one jab from Janssen equals 66.8% of the population while about 30.7% of the population opted for a booster dose.

Meanwhile, TrialSite, on several occasions, has chronicled a global glut of COVID-19 vaccines and therapeutics, especially in places like India, the world’s second-highest populated country. In places like Australia, where the death rate associated with COVID-19 has absolutely skyrocketed despite high immunization rates, the public health agencies and politicians continue to promote booster doses as the answer. TrialSite reported recently that Australian politicians in an election season essentially pretend that times are back to normal despite record numbers of cases, near-record hospitalizations, and double the deaths in the first months of 2022 than all of 2020 and 2021 combined.

Some Possible Explanations

Reuters’ Michael Erman and Manas Mishra write that vaccine producers such as Novavax and CureVac, the German mRNA-vaccine maker in partnership with GlaxoSmithKline, seek to target this booster market. Novavax still awaits FDA authorization despite the fact that much of the developed world, from Europe to Canada and Japan to the WHO, have authorized the use of the Novavax vaccine.

Meanwhile, the outlook for Janssen and AstraZeneca (Oxford) is that bright, report the Reuters journalists. According to Hartaj Singh, an analyst from Oppenheimer & Co., “It becomes a very competitive game with companies battling it out with pricing and for market share, even for vaccines that are considered to be the best, like Pfizer and Moderna.”

Interestingly, Pfizer’s CEO Albert Bourla went on the record in an interview recently that those adults that have opted to receive a COVID-19 vaccine are not likely to start accepting shots now in a recognition that the mega push for vaccine administration has come and gone.

Moderna has pegged the unfolding market as the annual shot market, targeting the following:

  • Adults 50 and above
  • People with comorbidities or other risks
  • High-risk occupations (e.g., healthcare, etc.)

According to the estimates of Stephane Bancel, Moderna’s CEO, this emerging annual shot market totals 1.7 billion, representing 21% of the global population. The mRNA-based vaccines are more expensive and cumbersome to distribute and store, hence a sizeable chunk of that estimated target may opt for other vaccines such as the two recently touted by vaccine insiders at WHO including a plant-based vaccine from Canada and one from China. 

More than likely Western Europe and America will represent central markets for sales for Pfizer and Moderna who will move toward more competitive, targeted responsive strategies as large government pre-purchases are probably going to be far less. Moreover, TrialSite suggests what were cozy relationships between industry and government agencies will become less so as the various governments’ responses to the pandemic will be a hot topic, especially in democracies in current election cycles.

Key Question: A flu shot model or something else?

The Reuters writers posed an important question in the recent piece: will the likes of Pfizer and Moderna starting this fall market a tailored, redesigned vaccine targeted relevant variants of concern (e.g., Omicron, BA.2, etc.)?

Both Moderna and Pfizer executives are on the record that they are developing Omicron-targeted vaccines.

This becomes an important topic as even the mainstream media starts to become slightly critical of the pandemic response, including mRNA-based vaccine makers that never modified the vaccine product once. The vaccine authorized and approved in the United States was developed based on the original Wuhan variant of SARS-CoV-2 which didn’t seem to make it in circulation to America nor most of the world.

Revenues Decline (but still unprecedented)

2023 sales numbers, while still staggering as compared to historical precedent in the pharmaceutical industry, are nonetheless, on the decline. Reuters reports $17 billion projected for Pfizer-BioNTech (down nearly half from $34 billion) and $10 billion for Moderna as compared to $23 billion in 2022. Sales will continue to drop because enormous fortunes were generated in the winner-take-all pandemic market.

TrialSite suggests the COVID-19 pandemic response must be seriously evaluated due to levels of bias, political interference, and potentially corruption at an unprecedented level. Should the political conditions change in the United States for example, leading to serious inquiries, the pandemic winners may incur unexpected costs.

After 16 months of major COVID-19 immunization initiatives worldwide, government appetite for COVID-19 vaccine products appears to morph into a more focused, market-based, targeted booster series, a change that vaccine producers are now adjusting to accommodate. With a confluence of forces, from COVID-19 vaccine gluts to increasing numbers of producers to leeriness of waning effectiveness due to highly transmissible variants, the market drivers, heavily driven by government, give way to an unfolding new reality.

In the United States, like in many other nations, including those aligned with the World Health Organization (WHO), centered responses to COVID-19 emphasized production and distribution of a maximum number of vaccines with targets of achieving at least 70% vaccination. That effort, again coordinated to some degree by groups such as WHO, led to the inoculation of about 4.68 billion people (according to Our World in Data) worldwide, or neatly 60% of humanity, representing an unprecedented pandemic response.

Johnson & Johnson Vaccine Recall


Armstrong Economics Blog/Vaccine Re-Posted May 9, 2022 by Martin Armstrong

The FDA has finally admitted what we knew all along – the vaccine is not safe. The FDA said it is limiting the availability of Johnson & Johnson’s COVID-19 vaccine as it does indeed cause blood clots. The agency also noted that the vaccine presents a risk of thrombosis with thrombocytopenia syndrome.

The health agencies are still pushing the vaccines from Moderna and Pfizer. How are they any different? The US government has a long history of punishing Johnson & Johnson for their illegal activities, from asbestos-laced baby powder to cancerogenic sunscreen. Yet, all pharmaceutical manufacturers are exempt from penalty for the COVID-19 vaccine, citing a national emergency.

FDA’s vaccine chief Dr. Peter Marks said that the risk of death is still better than not getting the jab and said Johnson & Johnson’s version may be used as a last resort. Johnson & Johnson was hoping to rake in $3.5 billion this year from the vaccine alone. All of this comes down to money and control. The government and businesses forced mandates with complete disregard for public health. The talking heads gaslit the world for years into believing anyone who questioned the vaccine was a conspiracy theory lunatic, unfit for society.

They have known the truth all along. The Johnson & Johnson vaccine came into question in April 2021. Here is Fauci maintaining that the Johnson & Johnson vaccine was “safe and effective” despite knowing it could be deadly:

FDA Limits Use of Johnson and Johnson Vaccine Due to Blood Clots


Posted originally on the conservative tree house on May 5, 2022 | Sundance 

The FDA has limited the use of the Johnson and Johnson COVID vaccine to only those over 18-years-old due to blood clotting issues. [Press Release Here] Johnson & Johnson’s Covid-19 vaccine is now limited to adults due to the risk of a rare blood clotting syndrome.

FDA – “Today, the U.S. Food and Drug Administration has limited the authorized use of the Janssen COVID-19 Vaccine to individuals 18 years of age and older for whom other authorized or approved COVID-19 vaccines are not accessible or clinically appropriate, and to individuals 18 years of age and older who elect to receive the Janssen COVID-19 Vaccine because they would otherwise not receive a COVID-19 vaccine.” (read more)

WHAT CHANGED? – “The FDA and CDC have continuously monitored for and investigated all suspected cases of TTS reported to VAERS. In an updated analysis of TTS cases following administration of the Janssen COVID-19 Vaccine that were reported to VAERS through March 18, 2022, the FDA and CDC have identified 60 confirmed cases, including nine fatal cases. The FDA has determined that the reporting rate of TTS is 3.23 per million doses of vaccine administered and the reporting rate of TTS deaths is 0.48 per million doses of vaccine administered.”

Mandatory Mask Theater Returns, CDC Announces Long Term Extension for Biden Transporation Mask Mandate, No Expiration Date, Planes, Trains and Busses


Posted originally on the conservative tree house on May 3, 2022 | Sundance 

Previously a federal judge overturned the federal mask mandate for transportation, thereby allowing travelers to make their own choices.  The DOJ has appealed that decision after the CDC said it wanted the mask mandate to remain in place.  The status of that litigation is unknown.

Today, the CDC has announced a semi-permanent extension of the federal transportation mask mandate with no expiration date noted. [Announcement Here] That means all travelers on airplanes, trains, busses and ridesharing will be required to wear facemasks again, including inside the terminals and operational hubs of those transportation nodes, pending the outcome of the DOJ appeal to the federal court.

CDC Announcement – “At this time, CDC recommends that everyone aged 2 and older – including passengers and workers – properly wear a well-fitting mask or respirator over the nose and mouth in indoor areas of public transportation (such as airplanes, trains, etc.) and transportation hubs (such as airports, stations, etc.).

[…] This public health recommendation is based on the currently available data, including an understanding of domestic and global epidemiology, circulating variants and their impact on disease severity and vaccine effectiveness, current trends in COVID-19 Community Levels within the United States, and projections of COVID-19 trends in the coming months.

[…]  “CDC continues to recommend that all people—passengers and workers, alike—properly wear a well-fitting mask or respirator in indoor public transportation conveyances and transportation hubs to provide protection for themselves and other travelers in these high volume, mixed population settings. […] Additionally, it is important for all of us to protect not only ourselves, but also to be considerate of others at increased risk for severe COVID-19 and those who are not yet able to be vaccinated. Wearing a mask in indoor public transportation settings will provide protection for the individual and the community.”  ~ Rochelle Walensky, CDC Director

If the Biden administration lose the court appeal to reinstitute the mask mandate, this announcement by the CDC would appear to be moot, they couldn’t enforce it.  However, if the Biden administration is successful in their appeal, the mandatory mask wearing returns.

Put another way….. If the Biden administration lose the appeal, the people wearing masks will be the COVID worshippers.  If the Biden administration win their appeal we all have to wear them.

The mandate created by Joe Biden did not have legal structure.  It was a dictatorial fiat that exceeded the capacity of the executive branch to create.  U.S. District Judge Kathryn Kimball Mizelle found the CDC exceeded its statutory authority with the mask mandate and violated the rules that guide CDC regulations.   {LINK} After Joe Biden arbitrarily announced the federal transportation mandate, the CDC triggered enforcement of the mask mandate without any required time for public feedback on a new regulation.

Congress could easily write a law authorizing mechanisms for the CDC and TSA to use in enforcement of a federal Transportation mask mandate; but they won’t – because the public doesn’t support it.  However, the Biden administration doesn’t care about majority public opinion, they are fine-tuned to push virtue signaling as a political strategy.

The White House is very committed to all their mandates around COVID-19, the mask mandate is no different.  From the perspective of the professional political left, the theater of forced mask wearing represents the visible power and authority of government to rule the lives of the irrelevant proles.

Any pesky legal rulings, that seek to reduce or remove the power of government, are viewed by the left as arbitrary and insignificant efforts to block their almighty power of government.  They can choose to wear a mask if they want, but that’s not really the issue behind the mask mandate.  The true power of the left is in the ability to force everyone to comply to their whims regardless of individual freedom.

The Covidians who define themselves by their adherence to the dictates of the U.S. government, will be happy with this position from the CDC today. They worship at the altar of COVID science and use masks as an expression of their sanctimonious feeling of superiority.  However, in an election year where the overwhelming majority of the American people have had enough of this political science, this CDC position may fuel an even more angry response.

Moderna Poised to Commit Infanticide


Armstrong Economics Blog/Vaccine Re-Posted May 2, 2022 by Martin Armstrong

Moderna is officially coming for toddlers and infants under five. The company submitted a formal request with the Food and Drug Administration (FDA), claiming the vaccine is 51% effective among toddlers under two and 37% effective in the two to five-year-old range. Instead of the standard two-100 microgram doses, the youngest among the population will receive two 25-microgram doses.

“I think it is likely that over time they will need additional doses. But we’re working on that,” Moderna’s Chief Medical Officer Dr. Paul Burton stated.

They will continue to force vaccines on everyone in the population. There is no telling the long-term effects of injecting a gene-altering medication into a baby, but Big Pharma is willing to risk lives for profits and government is will risk lives to retain control over a scared and uninformed population. Only 475 children under five have died from COVID, according to the Associated Press. There is absolutely no need for a vaccination for this demographic.

There are reports of babies dying through breast milk contaminated with the vaccination. Countless top doctors have warned against vaccinating children in general. Even the World Health Organization has even admitted that healthy adolescents do not need boosters, despite Pfizer filing a claim to have theirs approved for the five to twelve-year-old kids. Not to be outdone, Pfizer said it will have a vaccine for babies by the summer.

Since parents are reluctant to destroy their child’s development, the powers that be will continue to force mandates. They will push for universal passports to document everyone, including the youngest, most vulnerable members of society. They want us to inject ourselves repeatedly from birth until death for a virus that even Fauci no longer calls a pandemic.

Why Are We More Divided Than During the Civil War? | Dennis Prager | POLITICS | Rubin Report


Posted originally on The Rubin Report  Published February 27, 2022 33,229 Views

Dave Rubin of “The Rubin Report” talks to PragerU founder Dennis Prager about the dangers of political polarization, why he is a former Democrat, why people think conservatives are evil, and why black workers always do worse with Democratic policies. First, Dennis explains why this period of political tribalism is so concerning and why the political divide may actually be more dangerous than the civil war. He explains why he won’t be leaving California and joining the blue state exodus to states like Florida and Texas. He also explains how he went from a Jimmy Carter voting former liberal to a promoter of conservative values. Next, Dennis shares a GK Chesterton quote that explains why a secular society may not be as good as it sounds and how secularism can lead to new religions like wokeness. He explains how the left no longer believes in science and how he was mocked on “Real Time with Bill Maher” for pointing out that the left now believes men can menstruate. Now only two years later, Bill Maher is attacking things like the pregnant man emoji. Dennis also explains how successful liberals have been at creating the myth of evil Republicans and why his first Republican vote was one of the hardest things he ever did. Finally, Dennis explains how liberal policies like those enacted by LA county DA George Gascón only make crime and public safety much worse. He shares how even an anti-Trump conservative like Jason Riley can see how Trump’s policies reduced black unemployment, yet black voters ignore this reality and continue to vote Democrat. Why do the crimes of the left by the people like Joseph Stalin and Chairman Mao get forgotten or ignored and who will pay for the lockdown mistake and COVID tyranny?

Australia – One Giant Step for Klaus Schwab – You Will Own Nothing!


Armstrong Economics Blog/Australia & Oceania Re-Posted May 1, 2022 by Martin Armstrong

Spread the love

Believe it or not, Australia wants to buy your home. Under the scheme, homebuyers will no longer need to pay Lenders Mortgage Insurance (LMI), which will save the people potentially more than $30,000. The initial proposal is they will buy 40% of your home. Like the income tax was only to be for the rich, the end of the story is in fact Klaus Schwab’s Agenda 2030 – you will own nothing because all debt will be wiped out – DEFAULT.